CYP4 enzymes as potential drug targets: Focus on enzyme multiplicity, inducers and inhibitors, and therapeutic modulation of 20- hydroxyeicosatetraenoic acid (20-HETE) synthase and fatty acid ω-hydroxylase activities

Current Topics in Medicinal Chemistry

Volumn 13, Issue 12, 2013, Pages 1429-1440

  Edson, Katheryne Z ^a   Rettie, Allan E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

20 HETE; Cancer; CYP4; HET0016; Hypertension; Refsum disease; Stroke; X ALD

Indexed keywords

(N HYDROXY N? (4 N BUTYL 2 METHYLPHENYL) FORMAMIDINE); 17 OCTADECYNOIC ACID; 20 HYDROXYICOSATETRAENOIC ACID; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ALKANE 1 MONOOXYGENASE; ARACHIDONIC ACID; CARBOXYLIC ACID; COMPACTIN; CYTOCHROME P450; CYTOCHROME P450 4; CYTOCHROME P450 4A11; DEXAMETHASONE; FIBRIC ACID DERIVATIVE; GENISTEIN; HET 0016; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; LIPOPROTEIN RECEPTOR; MEVINOLIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLACEBO; PREGNANE X RECEPTOR; PROGESTERONE; PROSTAGLANDIN A1; PROSTAGLANDIN H2; PROTEIN KINASE C; RESVERATROL; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ADENOCARCINOMA; ADRENOLEUKODYSTROPHY; BLEEDING DISORDER; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME SPECIFICITY; FATTY ACID OXIDATION; GENE CLUSTER; GENETIC DISORDER; GENETIC REGULATION; GENETIC TRANSCRIPTION; HUMAN; HYPERTENSION; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFSUM DISEASE; REVIEW; SEQUENCE HOMOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; WESTERN BLOTTING;

ALKANE 1-MONOOXYGENASE; ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84881338069     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/15680266113139990110     Document Type: Review

References (95)

1. Hoch, U.; Ortiz De Montellano, P.R. Covalently linked heme in cytochrome p4504a fatty acid hydroxylases. The Journal of biological chemistry, 2001, 276(14), 11339-11346.
2. Henne, K.R.; Kunze, K.L.; Zheng, Y.M.; Christmas, P.; Soberman, R.J.; Rettie, A.E. Covalent linkage of prosthetic heme to CYP4 family P450 enzymes. Biochemistry, 2001, 40(43), 12925-12931.
3. Bylund, J.; Hidestrand, M.; Ingelman-Sundberg, M.; Oliw, E.H. Identification of CYP4F8 in human seminal vesicles as a prominent 19-hydroxylase of prostaglandin endoperoxides. The Journal of biological chemistry, 2000, 275(29), 21844-21849.
4. Bylund, J.; Bylund, M.; Oliw, E.H. cDna cloning and expression of CYP4F12, a novel human cytochrome P450. Biochemical and biophysical research communications, 2001, 280(3), 892-897.
5. Gainer, J.V.; Bellamine, A.; Dawson, E.P.; Womble, K.E.; Grant, S.W.; Wang, Y.; Cupples, L.A.; Guo, C.Y.; Demissie, S.; O'Donnell, C.J.; Brown, N.J.; Waterman, M.R.; Capdevila, J.H. Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation, 2005, 111(1), 63-69.
6. Dierks, E.A.; Zhang, Z.; Johnson, E.F.; de Montellano, P.R. The catalytic site of cytochrome P4504A11 (CYP4A11) and its L131F mutant. The Journal of biological chemistry, 1998, 273(36), 23055-23061.
7. Powell, P.K.; Wolf, I.; Jin, R.; Lasker, J.M. Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11. The Journal of pharmacology and experimental therapeutics, 1998, 285(3), 1327-1336.
8. Lasker, J.M.; Chen, W.B.; Wolf, I.; Bloswick, B.P.; Wilson, P.D.; Powell, P.K. Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. The Journal of biological chemistry, 2000, 275(6), 4118-4126.
9. Johnson, E.F.; Palmer, C.N.; Griffin, K.J.; Hsu, M.H. Role of the peroxisome proliferator-activated receptor in cytochrome P450 4A gene regulation. The FASEB journal: official publication of the Federation of American Societies for Experimental Biology, 1996, 10(11), 1241-1248.
10. Johnson, E.F.; Hsu, M.H.; Savas, U.; Griffin, K.J. Regulation of P450 4A expression by peroxisome proliferator activated receptors. Toxicology, 2002, 181, 203-206.
11. Lawrence, J.W.; Li, Y.; Chen, S.; DeLuca, J.G.; Berger, J.P.; Umbenhauer, D.R.; Moller, D.E.; Zhou, G. Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha. PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expresson. The Journal of biological chemistry, 2001, 276(34), 31521-31527.
12. Cattley, R.C.; DeLuca, J.; Elcombe, C.; Fenner-Crisp, P.; Lake, B.G.; Marsman, D.S.; Pastoor, T.A.; Popp, J.A.; Robinson, D.E.; Schwetz, B.; Tugwood, J.; Wahli, W. Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? Regulatory toxicology and pharmacology: RTP, 1998, 27(1 Pt 1), 47-60.
13. Savas, U.; Machemer, D.E.; Hsu, M.H.; Gaynor, P.; Lasker, J.M.; Tukey, R.H.; Johnson, E.F. Opposing roles of peroxisome proliferator-activated receptor alpha and growth hormone in the regulation of CYP4A11 expression in a transgenic mouse model. The Journal of biological chemistry, 2009, 284(24), 16541-16552.
14. Alvergnas, M.; Richert, L.; Blanchard, N.; Abadie, C.; Heyd, B.; Mantion, G.; Gallemann, D.; Martin, H. Regulation of CYP4A expression by bezafibrate in primary culture of rat and human hepatocytes: interspecies difference and influence of N-acetylcysteine. Toxicology in vitro: an international journal published in association with BIBRA, 2009, 23(7), 1259-1267.
15. Raucy, J.L.; Lasker, J.; Ozaki, K.; Zoleta, V. Regulation of CYP2E1 by ethanol and palmitic acid and CYP4A11 by clofibrate in primary cultures of human hepatocytes. Toxicological sciences: an official journal of the Society of Toxicology, 2004, 79(2), 233-241.
16. Cui, X.; Kawashima, H.; Barclay, T.B.; Peters, J.M.; Gonzalez, F.J.; Morgan, E.T.; Strobel, H.W. Molecular cloning and regulation of expression of two novel mouse CYP4F genes: expression in peroxisome proliferator-activated receptor alpha-deficient mice upon lipopolysaccharide and clofibrate challenges. The Journal of pharmacology and experimental therapeutics, 2001, 296(2), 542-550.
17. Stark, K.; Torma, H.; Cristea, M.; Oliw, E.H. Expression of CYP4F8 (prostaglandin H 19-hydroxylase) in human epithelia and prominent induction in epidermis of psoriatic lesions. Archives of biochemistry and biophysics, 2003, 409(1), 188-196.
18. Nilsson, T.; Ivanov, I.V.; Oliw, E.H. LC-MS/MS analysis of epoxyalcohols and epoxides of arachidonic acid and their oxygenation by recombinant CYP4F8 and CYP4F22. Archives of biochemistry and biophysics, 2010, 494(1), 64-71.
19. Kelly, E.J.; Nakano, M.; Rohatgi, P.; Yarov-Yarovoy, V.; Rettie, A.E. Finding homes for orphan cytochrome P450s: CYP4V2 and CYP4F22 in disease states. Molecular interventions, 2011, 11(2), 124-132.
20. Cui, X.; Nelson, D.R.; Strobel, H.W. A novel human cytochrome P450 4F isoform (CYP4F11): cDNA cloning, expression, and genomic structural characterization. Genomics, 2000, 68(2), 161-166.
21. Christmas, P.; Jones, J.P.; Patten, C.J.; Rock, D.A.; Zheng, Y.; Cheng, S.M.; Weber, B.M.; Carlesso, N.; Scadden, D.T.; Rettie, A.E.; Soberman, R.J. Alternative splicing determines the function of CYP4F3 by switching substrate specificity. The Journal of biological chemistry, 2001, 276(41), 38166-38172.
22. Hirani, V.; Yarovoy, A.; Kozeska, A.; Magnusson, R.P.; Lasker, J.M. Expression of CYP4F2 in human liver and kidney: assessment using targeted peptide antibodies. Archives of biochemistry and biophysics, 2008, 478(1), 59-68.
23. McDonald, M.G.; Rieder, M.J.; Nakano, M.; Hsia, C.K.; Rettie, A.E. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Molecular pharmacology, 2009, 75(6), 1337-1346.
24. Jin, Y.; Zollinger, M.; Borell, H.; Zimmerlin, A.; Patten, C.J. CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis. Drug metabolism and disposition: the biological fate of chemicals, 2011, 39(2), 191-198.
25. Kawakami, H.; Ohtsuki, S.; Kamiie, J.; Suzuki, T.; Abe, T.; Terasaki, T. Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection. Journal of pharmaceutical sciences, 2011, 100(1), 341-352.
26. Hsu, M.H.; Savas, U.; Griffin, K.J.; Johnson, E.F. Regulation of human cytochrome P450 4F2 expression by sterol regulatory element-binding protein and lovastatin. The Journal of biological chemistry, 2007, 282(8), 5225-5236.
27. Goldstein, J.L.; DeBose-Boyd, R.A.; Brown, M.S. Protein sensors for membrane sterols. Cell, 2006, 124(1), 35-46.
28. Hsu, M.H.; Savas, U.; Lasker, J.M.; Johnson, E.F. Genistein, resveratrol, and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofura noside induce cytochrome P450 4F2 expression through an AMPactivated protein kinase-dependent pathway. The Journal of pharmacology and experimental therapeutics, 2011, 337(1), 125-136.
29. Weinberg, J.M. Lipotoxicity. Kidney international, 2006, 70(9), 1560-1566.
30. Antoun, J.; Goulitquer, S.; Amet, Y.; Dreano, Y.; Salaun, J.P.; Corcos, L.; Plee-Gautier, E. CYP4F3B is induced by PGA1 in human liver cells: a regulation of the 20-HETE synthesis. Journal of lipid research, 2008, 49(10), 2135-2141.
31. Mizukami, Y.; Sumimoto, H.; Takeshige, K. Induction of cytochrome CYP4F3A in all-trans-retinoic acid-treated HL60 cells. Biochemical and biophysical research communications, 2004, 314(1), 104-109.
32. Zhao, Z.; He, X.; Bi, Y.; Xia, Y.; Tao, N.; Li, L.; Ma, Q. Induction of CYP4F3 by benzene metabolites in human white blood cells in vivo in human promyelocytic leukemic cell lines and ex vivo in human blood neutrophils. Drug metabolism and disposition: the biological fate of chemicals, 2009, 37(2), 282-291.
33. Wang, Y.; Bell, J.C.; Keeney, D.S.; Strobel, H.W. Gene regulation of CYP4F11 in human keratinocyte HaCaT cells. Drug metabolism and disposition: the biological fate of chemicals, 2010, 38(1), 100-107.
34. Bell, J.C.; Strobel, H.W. Regulation of cytochrome P450 4F11 by nuclear transcription factor-kappaB. Drug metabolism and disposition: the biological fate of chemicals, 2012, 40(1), 205-211.
35. Hariparsad, N.; Chu, X.; Yabut, J.; Labhart, P.; Hartley, D.P.; Dai, X.; Evers, R. Identification of pregnane-X receptor target genes and coactivator and corepressor binding to promoter elements in human hepatocytes. Nucleic acids research, 2009, 37(4), 1160-1173.
36. Zheng, Y.M.; Henne, K.R.; Charmley, P.; Kim, R.B.; McCarver, D.G.; Cabacungan, E.T.; Hines, R.N.; Rettie, A.E. Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-XArg motif critical to CYP4B1 catalysis. Toxicology and applied pharmacology, 2003, 186(2), 119-126.
37. Baer, B.R.; Rettie, A.E. CYP4B1: an enigmatic P450 at the interface between xenobiotic and endobiotic metabolism. Drug metabolism reviews, 2006, 38(3), 451-476.
38. Fisher, M.B.; Zheng, Y.M.; Rettie, A.E. Positional specificity of rabbit CYP4B1 for omega-hydroxylation1 of short-medium chain fatty acids and hydrocarbons. Biochemical and biophysical research communications, 1998, 248(2), 352-355.
39. Nakano, M.; Kelly, E.J.; Rettie, A.E. Expression and characterization of CYP4V2 as a fatty acid omega-hydroxylase. Drug metabolism and disposition: the biological fate of chemicals, 2009, 37(11), 2119-2122.
40. Savas, U.; Hsu, M.H.; Griffin, K.J.; Bell, D.R.; Johnson, E.F. Conditional regulation of the human CYP4X1 and CYP4Z1 genes. Archives of biochemistry and biophysics, 2005, 436(2), 377-385.
41. Kroetz, D.L.; Xu, F. Regulation and inhibition of arachidonic acid omega-hydroxylases and 20-HETE formation. Annual review of pharmacology and toxicology, 2005, 45, 413-438.
42. Sato, M.; Ishii, T.; Kobayashi-Matsunaga, Y.; Amada, H.; Taniguchi, K.; Miyata, N.; Kameo, K. Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor. Bioorganic & medicinal chemistry letters, 2001, 11(23), 2993-2995.
43. Miyata, N.; Taniguchi, K.; Seki, T.; Ishimoto, T.; Sato-Watanabe, M.; Yasuda, Y.; Doi, M.; Kametani, S.; Tomishima, Y.; Ueki, T.; Sato, M.; Kameo, K. HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme. British journal of pharmacology, 2001, 133(3), 325-329.
44. Kehl, F.; Cambj-Sapunar, L.; Maier, K.G.; Miyata, N.; Kametani, S.; Okamoto, H.; Hudetz, A.G.; Schulte, M.L.; Zagorac, D.; Harder, D.R.; Roman, R.J. 20-HETE contributes to the acute fall in cerebral blood flow after subarachnoid hemorrhage in the rat. American journal of physiology. Heart and circulatory physiology, 2002, 282(4), H1556-1565.
45. Parkinson, O.T.; Kelly, E.J.; Bezabih, E.; Whittington, D.; Rettie, A.E. Bioactivation of 4-Ipomeanol by a CYP4B enzyme in bovine lung and inhibition by HET0016. Journal of veterinary pharmacology and therapeutics, 2012, 35(4), 402-405.
46. Nakamura, T.; Sato, M.; Kakinuma, H.; Miyata, N.; Taniguchi, K.; Bando, K.; Koda, A.; Kameo, K. Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors. Journal of medicinal chemistry, 2003, 46(25), 5416-5427.
47. Miyata, N.; Seki, T.; Tanaka, Y.; Omura, T.; Taniguchi, K.; Doi, M.; Bandou, K.; Kametani, S.; Sato, M.; Okuyama, S.; Cambj-Sapunar, L.; Harder, D.R.; Roman, R.J. Beneficial effects of a new 20-hydroxyeicosatetraenoic acid synthesis inhibitor, TS-011 [N-(3-chloro-4-morpholin-4-yl) phenyl-N'-hydroxyimido formamide], on hemorrhagic and ischemic stroke. The Journal of pharmacology and experimental therapeutics, 2005, 314(1), 77-85.
48. Shak, S.; Reich, N.O.; Goldstein, I.M.; Ortiz de Montellano, P.R. Leukotriene B4 omega-hydroxylase in human polymorphonuclear leukocytes. Suicidal inactivation by acetylenic fatty acids. The Journal of biological chemistry, 1985, 260(24), 13023-13028.
49. Xu, F.; Straub, W.O.; Pak, W.; Su, P.; Maier, K.G.; Yu, M.; Roman, R.J.; Ortiz De Montellano, P.R.; Kroetz, D.L. Antihypertensive effect of mechanism-based inhibition of renal arachidonic acid omega-hydroxylase activity. American journal of physiology. Regulatory, integrative and comparative physiology, 2002, 283(3), R710-720.
50. Alonso-Galicia, M.; Drummond, H.A.; Reddy, K.K.; Falck, J.R.; Roman, R.J. Inhibition of 20-HETE production contributes to the vascular responses to nitric oxide. Hypertension, 1997, 29(1 Pt 2), 320-325.
51. Williams, J.M.; Murphy, S.; Burke, M.; Roman, R.J. 20-hydroxyeicosatetraeonic acid: a new target for the treatment of hypertension. Journal of cardiovascular pharmacology, 2010, 56(4), 336-344.
52. Dunn, K.M.; Renic, M.; Flasch, A.K.; Harder, D.R.; Falck, J.; Roman, R.J. Elevated production of 20-HETE in the cerebral vasculature contributes to severity of ischemic stroke and oxidative stress in spontaneously hypertensive rats. American journal of physiology. Heart and circulatory physiology, 2008, 295(6), H2455-2465.
53. Miyata, N.; Roman, R.J. Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi, 2005, 41(4), 175-193.
54. Alexanian, A.; Miller, B.; Roman, R.J.; Sorokin, A. 20-HETEproducing Enzymes Are Up-regulated in Human Cancers. Cancer genomics & proteomics, 2012, 9(4), 163-169.
55. Greene, E.R.; Huang, S.; Serhan, C.N.; Panigrahy, D. Regulation of inflammation in cancer by eicosanoids. Prostaglandins & other lipid mediators, 2011, 96(1-4), 27-36.
56. Simon, L.S. Role and regulation of cyclooxygenase-2 during inflammation. The American journal of medicine, 1999, 106(5B), 37S-42S.
57. Vanhoutte, P.M. COX-1 and vascular disease. Clinical pharmacology and therapeutics, 2009, 86(2), 212-215.
58. Feletou, M.; Huang, Y.; Vanhoutte, P.M. Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. British journal of pharmacology, 2011, 164(3), 894-912.
59. Harder, D.R.; Campbell, W.B.; Roman, R.J. Role of cytochrome P-450 enzymes and metabolites of arachidonic acid in the control of vascular tone. Journal of vascular research, 1995, 32(2), 79-92.
60. Harmon, S.D.; Fang, X.; Kaduce, T.L.; Hu, S.; Raj Gopal, V.; Falck, J.R.; Spector, A.A. Oxygenation of omega-3 fatty acids by human cytochrome P450 4F3B: effect on 20-hydroxyeicosatet raenoic acid production. Prostaglandins, leukotrienes, and essential fatty acids, 2006, 75(3), 169-177.
61. Tang, Z.; Salamanca-Pinzon, S.G.; Wu, Z.L.; Xiao, Y.; Guengerich, F.P. Human cytochrome P450 4F11: heterologous expression in bacteria, purification, and characterization of catalytic function. Archives of biochemistry and biophysics, 2010, 494(1), 86-93.
62. Alonso-Galicia, M.; Falck, J.R.; Reddy, K.M.; Roman, R.J. 20-HETE agonists and antagonists in the renal circulation. The American journal of physiology, 1999, 277(5 Pt 2), F790-796.
63. Cheng, J.; Ou, J.S.; Singh, H.; Falck, J.R.; Narsimhaswamy, D.; Pritchard, K.A. Jr.; Schwartzman, M.L. 20-hydroxyeicosatet raenoic acid causes endothelial dysfunction via eNOS uncoupling. American journal of physiology. Heart and circulatory physiology, 2008, 294(2), H1018-1026.
64. Kroetz, D.L.; Zeldin, D.C. Cytochrome P450 pathways of arachidonic acid metabolism. Current opinion in lipidology, 2002, 13(3), 273-283.
65. Sarkis, A.; Lopez, B.; Roman, R.J. Role of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids in hypertension. Current opinion in nephrology and hypertension, 2004, 13(2), 205-214.
66. Sarkis, A.; Roman, R.J. Role of cytochrome P450 metabolites of arachidonic acid in hypertension. Current drug metabolism, 2004, 5(3), 245-256.
67. Sun, C.W.; Falck, J.R.; Harder, D.R.; Roman, R.J. Role of tyrosine kinase and PKC in the vasoconstrictor response to 20-HETE in renal arterioles. Hypertension, 1999, 33(1 Pt 2), 414-418.
68. Gebremedhin, D.; Lange, A.R.; Narayanan, J.; Aebly, M.R.; Jacobs, E.R.; Harder, D.R. Cat cerebral arterial smooth muscle cells express cytochrome P450 4A2 enzyme and produce the vasoconstrictor 20-HETE which enhances L-type Ca2+ current. The Journal of physiology, 1998, 507(Pt 3), 771-781.
69. Gebremedhin, D.; Lange, A.R.; Lowry, T.F.; Taheri, M.R.; Birks, E.K.; Hudetz, A.G.; Narayanan, J.; Falck, J.R.; Okamoto, H.; Roman, R.J.; Nithipatikom, K.; Campbell, W.B.; Harder, D.R. Production of 20-HETE and its role in autoregulation of cerebral blood flow. Circulation research, 2000, 87(1), 60-65.
70. Harder, D.R.; Gebremedhin, D.; Narayanan, J.; Jefcoat, C.; Falck, J.R.; Campbell, W.B.; Roman, R. Formation and action of a P-450 4A metabolite of arachidonic acid in cat cerebral microvessels. The American journal of physiology, 1994, 266(5 Pt 2), H2098-2107.
71. Gross, E.R.; Nithipatikom, K.; Hsu, A.K.; Peart, J.N.; Falck, J.R.; Campbell, W.B.; Gross, G.J. Cytochrome P450 omegahydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal KATP channel. Journal of molecular and cellular cardiology, 2004, 37(6), 1245-1249.
72. Nithipatikom, K.; Gross, E.R.; Endsley, M.P.; Moore, J.M.; Isbell, M.A.; Falck, J.R.; Campbell, W.B.; Gross, G.J. Inhibition of cytochrome P450omega-hydroxylase: a novel endogenous cardioprotective pathway. Circulation research, 2004, 95(8), e65-71.
73. Pat Kunert, M.; Drenjancevic, I. 20-hydroxyeicosatetraenoic acid, endothelial dysfunction and hypertension. Medicinski glasnik: official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina, 2011, 8(2), 170-180.
74. Stec, D.E.; Roman, R.J.; Flasch, A.; Rieder, M.J. Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiological genomics, 2007, 30(1), 74-81.
75. Liu, H.; Zhao, Y.; Nie, D.; Shi, J.; Fu, L.; Li, Y.; Yu, D.; Lu, J. Association of a functional cytochrome P450 4F2 haplotype with urinary 20-HETE and hypertension. Journal of the American Society of Nephrology: JASN, 2008, 19(4), 714-721.
76. Fava, C.; Montagnana, M.; Almgren, P.; Rosberg, L.; Lippi, G.; Hedblad, B.; Engstrom, G.; Berglund, G.; Minuz, P.; Melander, O. The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure. Hypertension, 2008, 52(2), 373-380.
77. Kaspera, R.; Totah, R.A. Epoxyeicosatrienoic acids: formation, metabolism and potential role in tissue physiology and pathophysiology. Expert opinion on drug metabolism & toxicology, 2009, 5(7), 757-771.
78. Renic, M.; Klaus, J.A.; Omura, T.; Kawashima, N.; Onishi, M.; Miyata, N.; Koehler, R.C.; Harder, D.R.; Roman, R.J. Effect of 20-HETE inhibition on infarct volume and cerebral blood flow after transient middle cerebral artery occlusion. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism, 2009, 29(3), 629-639.
79. Chuang, S.S.; Helvig, C.; Taimi, M.; Ramshaw, H.A.; Collop, A.H.; Amad, M.; White, J.A.; Petkovich, M.; Jones, G.; Korczak, B. CYP2U1, a novel human thymus-and brain-specific cytochrome P450, catalyzes omega-and (omega-1)-hydroxylation of fatty acids. The Journal of biological chemistry, 2004, 279(8), 6305-6314.
80. Chen, P.; Guo, M.; Wygle, D.; Edwards, P.A.; Falck, J.R.; Roman, R.J.; Scicli, A.G. Inhibitors of cytochrome P450 4A suppress angiogenic responses. The American journal of pathology, 2005, 166(2), 615-624.
81. Moreno, J.J. New aspects of the role of hydroxyeicosatetraenoic acids in cell growth and cancer development. Biochemical pharmacology, 2009, 77(1), 1-10.
82. Guo, M.; Roman, R.J.; Falck, J.R.; Edwards, P.A.; Scicli, A.G. Human U251 glioma cell proliferation is suppressed by HET0016 [N-hydroxy-N'-(4-butyl-2-methylphenyl)formamidine], a selective inhibitor of CYP4A. The Journal of pharmacology and experimental therapeutics, 2005, 315(2), 526-533.
83. Guo, M.; Roman, R.J.; Fenstermacher, J.D.; Brown, S.L.; Falck, J.R.; Arbab, A.S.; Edwards, P.A.; Scicli, A.G. 9L gliosarcoma cell proliferation and tumor growth in rats are suppressed by Nhydroxy-N'-(4-butyl-2-methylphenol) formamidine (HET0016), a selective inhibitor of CYP4A. The Journal of pharmacology and experimental therapeutics, 2006, 317(1), 97-108.
84. Alexanian, A.; Rufanova, V.A.; Miller, B.; Flasch, A.; Roman, R.J.; Sorokin, A. Down-regulation of 20-HETE synthesis and signaling inhibits renal adenocarcinoma cell proliferation and tumor growth. Anticancer research, 2009, 29(10), 3819-3824.
85. Kunau, W.H.; Dommes, V.; Schulz, H. beta-oxidation of fatty acids in mitochondria, peroxisomes, and bacteria: a century of continued progress. Progress in lipid research, 1995, 34(4), 267-342.
86. Wanders, R.J.; Vreken, P.; Ferdinandusse, S.; Jansen, G.A.; Waterham, H.R.; van Roermund, C.W.; Van Grunsven, E.G. Peroxisomal fatty acid alpha-and beta-oxidation in humans: enzymology, peroxisomal metabolite transporters and peroxisomal diseases. Biochemical Society transactions, 2001, 29(Pt 2), 250-267.
87. Wanders, R.J.; Komen, J.; Kemp, S. Fatty acid omega-oxidation as a rescue pathway for fatty acid oxidation disorders in humans. The FEBS journal, 2011, 278(2), 182-194.
88. Sanders, R.J.; Ofman, R.; Dacremont, G.; Wanders, R.J.; Kemp, S. Characterization of the human omega-oxidation pathway for omega-hydroxy-very-long-chain fatty acids. The FASEB journal: official publication of the Federation of American Societies for Experimental Biology, 2008, 22(6), 2064-2071.
89. Sanders, R.J.; Ofman, R.; Duran, M.; Kemp, S.; Wanders, R.J. Omega-oxidation of very long-chain fatty acids in human liver microsomes. Implications for X-linked adrenoleukodystrophy. The Journal of biological chemistry, 2006, 281(19), 13180-13187.
90. Singh, I.; Khan, M.; Key, L.; Pai, S. Lovastatin for X-linked adrenoleukodystrophy. The New England journal of medicine, 1998, 339(10), 702-703.
91. Singh, I.; Pahan, K.; Khan, M. Lovastatin and sodium phenylacetate normalize the levels of very long chain fatty acids in skin fibroblasts of X-adrenoleukodystrophy. FEBS letters, 1998, 426(3), 342-346.
92. Engelen, M.; Ofman, R.; Dijkgraaf, M.G.; Hijzen, M.; van der Wardt, L.A.; van Geel, B.M.; de Visser, M.; Wanders, R.J.; Poll-The, B.T.; Kemp, S. Lovastatin in X-linked adrenoleukodystrophy. The New England journal of medicine, 2010, 362(3), 276-277.
93. Verhoeven, N.M.; Jakobs, C. Human metabolism of phytanic acid and pristanic acid. Progress in lipid research, 2001, 40(6), 453-466.
94. Komen, J.C.; Wanders, R.J. Identification of the cytochrome P450 enzymes responsible for the omega-hydroxylation of phytanic acid. FEBS letters, 2006, 580(16), 3794-3798.
95. Wanders, R.J.; Komen, J.C. Peroxisomes, Refsum's disease and the alpha-and omega-oxidation of phytanic acid. Biochemical Society transactions, 2007, 35(Pt 5), 865-869.